Comparison of the Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil Vaccine to Prevent HPV Infection

Trial Profile

Comparison of the Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil Vaccine to Prevent HPV Infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; Human papillomavirus infections
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 13 Apr 2011 Results published in the JAMA: the Journal of the American Medical Association.
    • 13 Apr 2011 Status changed from active, no longer recruiting to completed.
    • 20 Feb 2009 Planned end date changed from 1 Nov 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top